Steve Henry


Biological Engineer
CEO Kode Biotech 

Professor Steve Henry is an academic with a difference. Like other professors, research is his professional life, but unlike many he believes commercialisation is an integral partner to successful research.

Having trained as a laboratory scientist specialising in transfusion medicine, Professor Henry completed a PhD at the University of Auckland. In the 1990s he worked in New Zealand, France and Sweden, and then moved to Sweden where he completed a second PhD.

In 1996 he started the biotechnology company Kode Biotech to commercialise his biosurface engineering technology – Kode technology. As the CEO of Kode Biotech and Professor in the AUT Centre for Kode Technology Innovation he is fully immersed in the true commercial environment, taking research to product and developing it for the market. In 2015 Kode Biotech won the Supreme NZ Innovator Award for their contribution to the Agalimmune anti-cancer therapy innovation.

With a range of Kode-based products in use throughout the world, and a significant pipeline of new products, Kode technology has the potential to significantly impact on research methods and diagnostic testing.

It was this blend of business and science that saw him selected as a finalist for the 2008 New Zealand Ernst and Young Entrepreneur of the Year and the 2011 recipient of the Royal Society of New Zealand's prestigious R.J. Scott medal.

Professor Steve Henry's extended academic profile

Kode Biotech website 

Last updated: 14-Sep-2016 3.49pm

The information on this page was correct at time of publication. For a comprehensive overview of AUT qualifications, please refer to the Academic Calendar.